BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of October 21, 2026, BCRX trades at $7.80 with a market cap of $2.03B and a P/E ratio of -5.64. BCRX moved -2.64% today. Year to date, BCRX is +3.33%; over the trailing twelve months it is +10.95%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $19.25. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for BCRX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $7.80 |
| Market Cap | $2.03B |
| P/E Ratio | -5.64 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.31 |
| 52-Week Low | $6.00 |
| Volume | 4.13M |
| Avg Volume | 0 |
| Revenue (TTM) | $940.61M |
| Net Income | $-384.67M |
| Gross Margin | 97.78% |
8 analysts cover BCRX: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.25.